EUCTR2016-005230-30-GB进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects with Cystic Fibrosis (HOPE-1 STUDY: HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS) - HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 91
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Ability to provide written, personally signed, and dated informed consent
- •- Ability to self-administer the investigational product
- •- Diagnosis of cystic fibrosis as determined by the 2008 Cystic Fibrosis Foundation Consensus Guidelines
- •- Percent predicted forced expiratory volume in 1 second (ppFEV1) between 40.0% and 80.0% for cohort 1 and between 50.0% and 80% for cohort 2
- •- Stable CF lung disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- BMI < 18 kg/m2
- •- Use of a Cystic fibrosis transmembrane conductance regulator (CFTR) corrector or potentiator during the study or within 60 days before screening
- •- The presence of significant and unstable comorbidities within 28 days before screening
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension - LVGYEUCTR2005-002692-33-DEilly ICOS LLC400
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury - NDSevere brain injuryMedDRA version: 9.1Level: LLTClassification code 10060690EUCTR2010-018283-16-ITBHR PHARMA, LLC1,180
进行中（未招募）
1 期
A Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Patients with Active Ankylosing Spondylitis or Non-Radiographic Axial SpondyloarthritisAnkylosing spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)EUCTR2016-003936-19-HUSUN Pharmaceuticals Global FZE180
进行中（未招募）
不适用
The study is designed to determine the safety and efficacy of Progesterone in patients with severe head injurySevere traumatic brain injuryMedDRA version: 17.0Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 100000004863EUCTR2010-018283-16-FIBHR Pharma, LLC1,180
进行中（未招募）
1 期
Study to evaluate the efficacy of IPI-145 administered in combination with rituximab vs placebo in combination with rituximab in subjects with previously treated CD20-positive FFollicular LymphomaEUCTR2013-002406-31-PLInfinity Pharmaceuticals, Inc400